The thrombogenicity of 6-azouridine.

Abstract

The antimetabolite 6-azauridine blocks the de novo synthesis of pyrimidines and causes increased serum levels of several amino acids including homocystine. 6-Azauridine was was withdrawn from clinical use for the treatment of psoriasis because of the occurence of arterial and venous thromboembolic episodes in some psoriatic patients. Utilizing a standard animal model for the recognition of venous and arterial thrombosis, 6-azauridine was demonstrated in this study to cause thrombosis without producing homocystinemia when administered orally or intravenously.

• Authors: S N Gitel, A J Grieco, S Wessler, S E Snyderman
• Journal: Haemostasis (Haemostasis) Vol. 8 Issue 1 Pg. 54-7 ( 1979) ISSN: 0301-0147 [Print] Switzerland
• PMID: 456945 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Azauridine

Topics

• Administration, Oral
• Animals
• Azauridine (administration & dosage, pharmacology)
• Blood Coagulation (drug effects)
• Dose-Response Relationship, Drug
• Injections, Intravenous
• Male
• Rabbits
• Thrombosis (etiology)